Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus PHILITH.
ENSKYCE vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
1 mg orally once daily
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive